Millipore Sigma Vibrant Logo

559388 SB 202190 - CAS 152121-30-7 - Calbiochem

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₂₀H₁₄FN₃O 152121-30-7

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
559388-1MG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA potent, reversible, competitive, and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (Ki = 16 nM; IC50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC50 = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to induce LDL receptor expression in Hep52 cells. A 1 mg/ml solution of SB 202190 (Cat. No. 559397) in anhydrous DMSO is also available.
      Catalogue Number559388
      Brand Family Calbiochem®
      Synonyms4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole, FHPI, p38 MAP Kinase Inhibitor II
      References
      ReferencesDavies, S.P., et al. 2000. Biochem. J. 351, 95.
      Ajizian, S.J., et al. 1999. J. Infect. Dis. 179, 939.
      Singh, R.P., et al. 1999. J. Biol. Chem. 274, 19593.
      Wang, S.W., et al. 1999. Inflamm. Res. 48, 533.
      Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49.
      LoGrasso, P.V., et al. 1997. Biochem. 36, 10422.
      Jiang, Y., et al. 1996. J. Biol. Chem. 271, 17920.
      Kramer, R.M., et al. 1996. J. Biol. Chem. 271, 27723.
      Li, Z., et al. 1996. Biochem. Biophys. Res. Commun. 228, 334.
      Lee, J.C., et al. 1994. Nature 372, 739.
      Product Information
      CAS number152121-30-7
      ATP CompetitiveY
      FormPale yellow solid
      Hill FormulaC₂₀H₁₄FN₃O
      Chemical formulaC₂₀H₁₄FN₃O
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetp38β
      Primary Target IC<sub>50</sub>350 nM against the kinase activity of p38β; 280 nM against p38 phosphorylation of activating transcription factor 2 (ATF-2)
      Primary Target K<sub>i</sub>16 nM
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      SB 202190 - CAS 152121-30-7 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      SB 202190 - CAS 152121-30-7 - Calbiochem Certificates of Analysis

      TitleLot Number
      559388

      References

      Reference overview
      Davies, S.P., et al. 2000. Biochem. J. 351, 95.
      Ajizian, S.J., et al. 1999. J. Infect. Dis. 179, 939.
      Singh, R.P., et al. 1999. J. Biol. Chem. 274, 19593.
      Wang, S.W., et al. 1999. Inflamm. Res. 48, 533.
      Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49.
      LoGrasso, P.V., et al. 1997. Biochem. 36, 10422.
      Jiang, Y., et al. 1996. J. Biol. Chem. 271, 17920.
      Kramer, R.M., et al. 1996. J. Biol. Chem. 271, 27723.
      Li, Z., et al. 1996. Biochem. Biophys. Res. Commun. 228, 334.
      Lee, J.C., et al. 1994. Nature 372, 739.

      Brochure

      Title
      MAPK Pathway Poster ( 750 KB )

      Citations

      Title
    • Annika Grabbe and Jurgen Wienands. (2006) Human SLP-65 isoforms contribute differently to activation and apoptosis of B lymphocytes. Blood 108, 3761-3768.
    • Patrick Michl, et al. (2005) CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7, 521-532.
    • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
    • Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-January-2010 RFH
      Synonyms4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole, FHPI, p38 MAP Kinase Inhibitor II
      DescriptionA potent, reversible, competitive, and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (Ki = 16 nM; IC50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC50 = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to induce LDL receptor expression in Hep52 cells.
      FormPale yellow solid
      CAS number152121-30-7
      Chemical formulaC₂₀H₁₄FN₃O
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage -20°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesDavies, S.P., et al. 2000. Biochem. J. 351, 95.
      Ajizian, S.J., et al. 1999. J. Infect. Dis. 179, 939.
      Singh, R.P., et al. 1999. J. Biol. Chem. 274, 19593.
      Wang, S.W., et al. 1999. Inflamm. Res. 48, 533.
      Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49.
      LoGrasso, P.V., et al. 1997. Biochem. 36, 10422.
      Jiang, Y., et al. 1996. J. Biol. Chem. 271, 17920.
      Kramer, R.M., et al. 1996. J. Biol. Chem. 271, 27723.
      Li, Z., et al. 1996. Biochem. Biophys. Res. Commun. 228, 334.
      Lee, J.C., et al. 1994. Nature 372, 739.
      Citation
    • Annika Grabbe and Jurgen Wienands. (2006) Human SLP-65 isoforms contribute differently to activation and apoptosis of B lymphocytes. Blood 108, 3761-3768.
    • Patrick Michl, et al. (2005) CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7, 521-532.
    • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
    • Related Products & Applications

      Alternative Products

      Catalog Number Description  
      559393 SB 202190, Hydrochloride - CAS 350228-36-3 - Calbiochem Show Pricing & Availability

      Related Products

      Catalog Number Description  
      559389 SB 203580 - CAS 152121-47-6 - Calbiochem Show Pricing & Availability
      559396 SB 220025 Show Pricing & Availability

      Categories

      Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Protein Phosphorylation / Dephosphorylation > MAP Kinase Inhibitors